10% Dextrose Na.K. 2

Adult administration

For typical adults, intravenous administration of 500-1000ml is given by infusion. The infusion rate should not exceed 0.5g of dextrose per kg of body weight per hour. The dosage and infusion rate should be appropriately adjusted based on age, weight, and symptoms.

This medication may cause a deficiency of vitamin B1 (thiamine) when administered intravenously, so caution is required. Allergic reactions or anaphylaxis may occur while using this drug; if any abnormal symptoms appear, discontinue administration immediately and seek appropriate treatment. Since the solution contains potassium, there is a risk of hyperkalemia, thus patients with impaired kidney function or certain heart conditions should be particularly cautious. Patients with diabetes or those who have difficulty managing blood sugar may experience a rapid increase in blood sugar levels due to this medication, so blood sugar should be monitored frequently, and insulin treatment should be administered if necessary. Elevated sodium and chloride concentrations can lead to electrolyte imbalance, and patients with heart or liver disease should be careful due to the risk of fluid overload and edema. Hyponatremia may occur, leading to neurological symptoms such as headache, vomiting, and seizures, so patients in at-risk groups should carefully monitor their serum sodium levels. Excessive fluid administration may worsen pulmonary edema or congestive heart failure, so the dosage and infusion rate should be adjusted carefully. In patients with very poor nutritional status, nutritional support should be initiated slowly, and potassium, phosphorus, and magnesium levels should be monitored closely to prevent refeeding syndrome. In patients with specific conditions such as hyperkalemia, fluid overload, hypernatremia, or hyperglycemia, it is advisable not to administer this medication. Patients with impaired kidney function or those with heart failure or obstructive uropathy should be particularly cautious when using this medication, and electrolyte and fluid status should be checked frequently. Overdosage of this medication may lead to cerebral edema, pulmonary edema, hyperkalemia, etc., so administration rates and dosages must be strictly managed. Special attention is required for pregnant or breastfeeding women, newborns, children, and the elderly when using this medication, and blood sugar and electrolyte status must be closely monitored. There may be interactions with other medications, so if taken concurrently with drugs that may cause hyperkalemia or blood sugar control medications, consult a doctor or pharmacist. In the event of overdose, treatment aimed at correcting serum potassium levels should be initiated immediately, and measures such as dialysis may be performed as necessary. This medication should be stored in a sealed container to protect it from air and moisture. The container is made of polypropylene or multilayer film plastic material. It is recommended to store the medication at room temperature, i.e., between 1°C and 30°C, to maintain its effectiveness over time.

Serious side effects

• Anaphylaxis
• severe rash with high fever
• cold sweat
• pallor
• severe swelling (edema)
• chest tightness
• difficulty breathing
• cardiac arrest
• hives
• cerebral edema

Mild side effects

• Rash
• itching
• extravasation
• venous thrombosis
• phlebitis
• pain at the injection site
• blistering at the injection site
• hyperkalemia
• hyperglycemia
• hyperosmolar hyperglycemic state

This medication should be stored in a sealed container to protect it from air or moisture. The container is made of polypropylene or multilayer film plastic material. It is advisable to keep the medication at room temperature, specifically between 1°C and 30°C, to ensure that the medication's effect is preserved.

Appearance

A colorless, transparent liquid in polypropylene or multilayer film plastic containers

Package unit

1000mL/box